4 Healthcare Stock Stories Prescribed for Investors
Neurocrine Biosciences (NASDAQ:NBIX): Closing price $9.19
On Wednesday the company announced that two additional patents have been granted related to its proprietary Vesicular Monoamine Transporter 2 inhibitor NBI-98854. European Patent Number 2,081,929 was granted in January by the European Patent Office, with an expiry date of November 2027, covering chemical compositions, pharmaceutical compositions and also uses of various compounds, among which include the firm’s Phase IIb clinical candidate NBI-98854. Additionally, the United States Patent and Trademark Office recently granted a second patent for NBI-98854.